NTHI Neonc Technologies Holdings, Inc.
USHealthcareAs of 2026-07-09 16:00
Why NTHI matters now
Neonc Technologies Holdings, Inc. (NTHI) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.49 with -0.00% on the session and $89.8M in market capitalization; recent performance reads 1-month -3.83% and YTD -36.28%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-8.8M, and EPS of $-0.38. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -20.6%.
The latest indexable market news headline is "Wall Street is Watching These Biotechs" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $15.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-9.28
P/S
0.00
EV/EBITDA
-3.00
DCF Value
$-0.71
FCF Yield
-20.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
284.3%
ROA
-1160.3%
ROIC
259.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-8.8M | $-0.38 |
| Q4 2025 | $0.00 | $-15.5M | $-0.81 |
| FY 2025 | $40.0K | $-62.1M | $-3.23 |
| Q3 2025 | $0.00 | $-8.6M | $-0.45 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$16.00
Target (Median)
$15.00
Target Range
$13.00 - $20.00
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.29
Neonc Technologies Holdings, Inc. specializes in pioneering molecular advancements aimed at improving the targeted administration of therapies for central nervous system disorders. The company's leading pipeline candidate, NEO100, is presently undergoing Phase 2a clinical trials for the treatment of glioblastoma. Additionally, NEO212, a unique molecular construct chemically linking the chemotherapeutic agent temozolomide with perillyl alcohol, has successfully concluded its preclinical evaluation. This enterprise, founded in 2023, operates from its base in Los Angeles, California.